1289 completed, 356 recruiting, 355 terminated, 342 unknown. 1705 Phase 2, 770 Phase 1, 546 Phase 3, 53 Not applicable, 25 Phase 4.
Follow Gemcitabine: new trials by email Literature Review of Gemcitabine trials Research Report on Gemcitabine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Resectable Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-12-10 | 2026-06-10 |
| HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. Gemcitabine (1000 mg/m^2), Paclitaxel 80 mg/m2 weekly - Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer | Phase 2 | Not yet recruiting | The University of The West Indies | 750 | 2027-06-01 | 2026-09-22 |
| Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma | Phase 3 | Not yet recruiting | CStone Pharmaceuticals | 150 | 2027-06-01 | 2026-05-27 |
| Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors Olaparib, Gemcitabine, Docetaxel - Germ Cell Cancer | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 36 | 2027-03-01 | 2026-10-01 |
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 125 | 2027-02-03 | 2026-08-06 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma. GnP, FOLFIRINOX - Pancreatic Adenocarcinoma Resectable, Non Metastatic | Phase 2 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 42 | 2027-01-01 | 2026-09-15 |
| A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | University of Chicago | 39 | 2026-12-12 | 2026-06-16 |
| Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. Nivolumab, Gemcitabine, Cisplatin - Advanced Biliary Tract Cancer(BTC) | Phase 2 | Withdrawn | National Health Research Institutes, Taiwan | 2026-12-01 | 2026-07-02 | |
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-09-17 |
| A Phase 3 Trial in Advanced Epithelioid Mesothelioma VT3989, gemcitabine, Vinorelbine - Pleural Mesothelioma, Mesothelioma | Phase 3 | Not yet recruiting | Vivace Therapeutics, Inc | 350 | 2026-12-01 | 2026-09-17 |
| Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Hospital Centre Biel/Bienne | 28 | 2026-12-01 | 2026-09-18 |
| Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic Cancer Gemcitabine (1000 mg/m2), Nab-paclitaxel, L-glutamine - Pancreatic Cancer | Phase 2 | Not yet recruiting | Jun Gong, MD | 200 | 2026-12-01 | 2026-10-08 |
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| Repurposing Mefloquine for Pancreatic Cancer Treatment Mefloquine, Modified FOLFIRINOX, gemcitabine and nab paclitaxel - Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | University of Florida | 36 | 2026-11-01 | 2026-10-15 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma Glofitamab, Gemcitabine, Oxaliplatin - PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 40 | 2026-11-01 | 2026-10-22 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-27 | 2026-10-08 |
Showing 20 of 2763. Sign in to see all of them.
Pancreatic Neoplasms (692) · Carcinoma, Non-Small-Cell Lung (331) · Neoplasms (175) · Breast Neoplasms (167) · Urinary Bladder Neoplasms (161) · Lung Neoplasms (159) · Neoplasm Metastasis (146) · Cholangiocarcinoma (119) · Ovarian Neoplasms (110) · Biliary Tract Neoplasms (102) · Lymphoma, Large B-Cell, Diffuse (77) · Nasopharyngeal Carcinoma (75) · Recurrence (67) · Lymphoma (66) · Gallbladder Neoplasms (63)
Eli Lilly and Company (105) · National Cancer Institute (NCI) (102) · M.D. Anderson Cancer Center (61) · Sun Yat-sen University (60) · Hoffmann-La Roche (50) · Memorial Sloan Kettering Cancer Center (46) · Alliance for Clinical Trials in Oncology (41) · AstraZeneca (36) · Fudan University (36) · Merck Sharp & Dohme LLC (31) · SWOG Cancer Research Network (24) · Sanofi (22) · Pfizer (19) · H. Lee Moffitt Cancer Center and Research Institute (18) · Bristol-Myers Squibb (17)
United States (1414) · China (527) · France (301) · Spain (291) · Italy (257) · Canada (248) · Germany (246) · United Kingdom (232) · South Korea (222) · Australia (181) · Belgium (181) · Japan (155) · Taiwan (141) · Poland (130) · Netherlands (114)
Cesare Gridelli, M.D. (8) · Armando Santoro, MD (7) · Dean Bajorin, MD (7) · Francesco Perrone, M.D., Ph.D. (7) · Jun Ma, M.D. (7) · Yago Nieto, MD, PHD (7)
PMID 37185961, PMID 31150573, PMID 31401903, PMID 34125951, PMID 37419867, PMID 39863139, PMID 40812353, PMID 20375404, PMID 23547081, PMID 28837405, PMID 29584545, PMID 30213452, PMID 34037241, PMID 37794220, PMID 10655437, PMID 16966687, PMID 18669454, PMID 21444871, PMID 21941283, PMID 23228446, PMID 23782814, PMID 24131140, PMID 25366678, PMID 25477010, PMID 25512461, PMID 25624439, PMID 27532020, PMID 27567280, PMID 29119276, PMID 29929491, PMID 30998813, PMID 33084020, PMID 33093337, PMID 33168398, PMID 33337539, PMID 33492986, PMID 33661301, PMID 33951890, PMID 34174189, PMID 34806163, PMID 35042534, PMID 35170751, PMID 35355438, PMID 36041086, PMID 37075781, PMID 37207654, PMID 37407274, PMID 38050737, PMID 38383458, PMID 38796193
2023 (34), 2016 (29), 2018 (25), 2017 (23), U10CA032102 (20), 2025 (19), 2015 (18), 2009 (16), U10CA031946 (16), 2019 (14), U10CA180820 (14), U10CA180868 (14), 2014 (12), P30CA015083 (10), P30CA022453 (10)